Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Anti-Inflammatory Effect of Inhaled AZD0449 in Healthy Volunteers and Mild Asthma
NCT03766399Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, single-blind trial of AZD0449 in asthma (6 arms), sponsored by AstraZeneca. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events, Maximum Observed Plasma Concentration and 1 more. Started Nov 2018; status: completed.
02
Drugs
AZD0449
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03766399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766399.